ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2576

uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis

Yan Liu1, Yunfeng Pan2 and Song Guo Zheng3, 1Center for Clinic Immunology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, 2Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, 3Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Angiogenesis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Urokinase-type plasminogen activator receptor (uPAR), is a multi-functional receptor on cell surface, widely present in endothelial cells, fibroblasts, and a variety of malignant cells. Current studies have suggested that uPAR overexpressed on synovial tissues or in synovial fluid or plasma in patients with rheumatoid arthritis (RA). However, there are limited researches regarding the role of uPAR on fibroblast-like synoviocytes of rheumatoid arthritis (RA-FLSs) and its underlying mechanisms. 

Methods: All synovial specimens were taken from patients, in which 8 patients with RA (met the 2009 ACR/EULAR criteria) , 4 patients with OA (consistent with 1995 ACR classification criteria) , and 3 patients with severe trauma who had , no other joint abnormalities or systemic disease. To study effects of uPAR on RA-FLSs, chemically synthesized small interference RNA(siRNA) specifically targeting the uPAR gene was transfected into RA-FLS by cationic liposome. Western blot and ELISA were taken to test inhibition efficiency. The proliferative inhibition rate was examined by the CCK8 assay. Flow cytometry was used to determine the change of cell cycle distribution and apoptosis. The migration and invasion ability of RA-FLSs were examined by a transwell assay. Western blot was performed to detect the influence of uPAR on the PI3K/Akt signaling pathway.Migration and tubule formation assays were used to explore the influence of RA-FLSs uPAR on angiogenesis.

Results:  Our studies show that the expression of uPAR protein was significantly higher in FLSs from RA than those from OA or traumatic injury patients. uPAR-siRNA could effectively block the uPAR expression of mRNA, protein level in RA-FLSs and soluble uPAR secretion in cell supernatant. uPAR gene silencing inhibited RA-FLSs proliferation by (28.62 ± 4.82)% at 72h, restrained cell transformation from the G0/G1 phase to S phase obviously, reduced RA-FLSs cell migration by (74.82 ± 2.16)% and invasion by (74.51 ± 4.73)% , and interfered with activation of the PI3K/Akt signaling pathway significantly. Cell supernatants from uPAR gene-silenced RA-FLSs markedly inhibited the migration and tubule formation ability of HUVEC (human umbilical vein endothelial cell ) (P <0.05).

Conclusion:

uPAR changes the biological characteristics of RA-FLSs and affects neoangiogenesis of synovial tissues in patients with RA, which may be associated with PI3K/Akt signaling pathway. These results imply that targeting of uPAR and its downstream signal pathway may provide beneficial therapeutic effects in RA.


Disclosure: Y. Liu, None; Y. Pan, None; S. G. Zheng, None.

To cite this abstract in AMA style:

Liu Y, Pan Y, Zheng SG. uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/upar-promotes-tumor-like-biologic-role-of-fibroblast-like-synoviocytes-through-pi3kakt-signaling-pathway-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/upar-promotes-tumor-like-biologic-role-of-fibroblast-like-synoviocytes-through-pi3kakt-signaling-pathway-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology